SCHEMBL29587191

CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 13)

	gene	UniProt	supporting neighbours	confidence
▸	F2	P00734	5/20	0.64

▸	CRHR1	P34998	1/20	0.59

▸	CRHR2	Q13324	1/20	0.59

▸	HCRTR1	O43613	1/20	0.58

▸	HCRTR2	O43614	1/20	0.58

▸	APLNR	P35414	1/20	0.56

▸	C5AR1	P21730	1/20	0.56

▸	NMUR2	Q9GZQ4	1/20	0.55

▸	NMBR	P28336	2/20	0.54

▸	GRPR	P30550	2/20	0.54

▸	CALCR	P30988	3/20	0.53

▸	MC4R	P32245	1/20	0.52

▸	NTSR1	P30989	1/20	0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29525577	0.92	APLNR (0.64)	APLNRMC4R
SCHEMBL29526046	0.92	APLNR (0.64)	APLNRMC4R
SCHEMBL29525492	0.92	APLNR (0.64)	APLNRMC4R
SCHEMBL29525147	0.89	APLNR (0.63)	APLNRC5AR1MC4R
SCHEMBL29526390	0.88	APLNR (0.64)	APLNRC5AR1
SCHEMBL29793956	0.85	C5AR1 (0.61)	F2C5AR1NMBRGRPR
SCHEMBL30980371	0.84	NMUR2 (0.61)	F2CRHR1CRHR2NMUR2NTSR1
SCHEMBL30355012	0.83	C5AR1 (0.63)	F2APLNRC5AR1NMBRGRPR
SCHEMBL30481466	0.82	HCRTR1 (0.56)	F2CRHR1CRHR2HCRTR1HCRTR2
SCHEMBL31182732	0.82	CALCR (0.69)	F2CRHR1CRHR2HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12415831-B2	HPLC free purification of peptides by the use of new capping and capture reagents	ROCHE DIAGNOSTICS OPERATIONS, INC. (US)	2025-09-16	—	—	US	disclosed
US-20250179130-A1	METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS	ON TARGET THERAPEUTICS LLC	2025-06-05	—	—	US	disclosed
US-12060397-B2	Soluble lipidated ligand agents for treating eye inflammation	TUFTS MEDICAL CENTER (US)	2024-08-13	—	—	US	disclosed
US-20220135633-A1	METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS	ON TARGET THERAPEUTICS LLC	2022-05-05	—	—	US	disclosed
US-20220064212-A1	HPLC FREE PURIFICATION OF PEPTIDES BY THE USE OF NEW CAPPING AND CAPTURE REAGENTS	ROCHE DIAGNOSTICS GMBH (DE)	2022-03-03	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20220135633-A1	METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS	LDLR, HDLBP, LIPG	F2 835/4885CRHR1 3476/4885CRHR2 3111/4885
US-12415831-B2	HPLC free purification of peptides by the use of new capping and capture reagents	RNGTT, PTMS, RNMT	F2 3912/4885CRHR1 805/4885CRHR2 909/4885
US-20220064212-A1	HPLC FREE PURIFICATION OF PEPTIDES BY THE USE OF NEW CAPPING AND CAPTURE REAGENTS	RNGTT, PTMS, RNMT	F2 3912/4885CRHR1 805/4885CRHR2 909/4885
US-20250179130-A1	METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS	LDLR, HDLBP, LIPG	F2 835/4885CRHR1 3476/4885CRHR2 3111/4885
US-12060397-B2	Soluble lipidated ligand agents for treating eye inflammation	LIPG, CD40, LDLR	F2 1454/4885CRHR1 2481/4885CRHR2 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.